Pesticides & Agrochemicals · Founded 2004 · www.shardacropchem.com · BSE 538666 · NSE SHARDACROP · ISIN INE221J01015
No Notes Added Yet
Business
Sharda Cropchem Ltd. is an India-based global agrochemical company specializing in the sourcing, formulation, registration, and distribution of post-patent (generic) agrochemical products. Its core business involves identifying off-patent active ingredients, obtaining necessary registrations for their sale in various countries, and then marketing and distributing these products. The company primarily operates an asset-light model, outsourcing manufacturing while focusing on intellectual property (registrations) and global market access. Beyond agrochemicals (herbicides, fungicides, insecticides), Sharda Cropchem also has a smaller but growing non-agrochemicals segment, which includes biocides, dyes, and industrial chemicals. It makes money through the sale of these registered products across diverse geographies.
Revenue Mix
The company's revenue primarily comes from two main segments:
Agrochemicals: This is the dominant segment, encompassing herbicides, fungicides, and insecticides. Herbicides typically contribute the largest share within this segment, followed by fungicides and insecticides.
Non-Agrochemicals: This segment includes a range of industrial applications such as biocides, dyes, and other industrial chemicals, contributing a smaller but significant portion of overall revenue.
Geographically, the company has a widespread presence, with Europe, NAFTA (North America), and Latin America being significant markets, alongside other regions globally.
Industry
The agrochemicals industry is characterized by the dominance of a few large multinational players holding patents on novel chemistries, alongside a fragmented generic segment. Sharda Cropchem operates primarily in the generic/post-patent segment. Its positioning is as a global player with an extensive network of product registrations across numerous countries. While it doesn't invent new molecules, it excels in the complex and time-consuming process of obtaining regulatory approvals for off-patent products, allowing it to compete effectively against other generic players and provide alternatives to patented products. Its asset-light model allows for flexibility and lower capital expenditure compared to integrated manufacturers.
MOAT
Sharda Cropchem's key competitive advantages include:
Extensive Registration Library & Regulatory Expertise: The company has a vast portfolio of product registrations across various geographies. Obtaining these registrations is a time-consuming, expensive, and technically complex process, acting as a significant barrier to entry for new competitors. This regulatory "IP" is a core asset.
Global Distribution Network: A widespread presence and established relationships with distributors across multiple continents enable efficient market access.
Asset-Light Model: By outsourcing manufacturing, the company maintains flexibility, lower capital intensity, and can adapt quickly to market demands without significant fixed costs.
Strong Supplier Relationships: Long-standing relationships with various active ingredient manufacturers, primarily in Asia, ensure a reliable supply chain.
Growth Drivers
New Product Registrations: Continuous filing and approval of new products and active ingredients in existing and new markets are the primary growth engine.
Geographic Expansion: Penetrating new countries and strengthening market share in existing regions.
Increasing Global Food Demand: The need to feed a growing population drives demand for crop protection products to enhance yields.
Genericization of Patented Molecules: As more agrochemical patents expire, new opportunities arise for generic players like Sharda Cropchem.
Portfolio Diversification: Growth in the non-agrochemicals segment and potential expansion into new chemistries.
Risks
Regulatory Changes: Stricter environmental regulations, product bans (e.g., for specific active ingredients like glyphosate), or delays in registration processes can significantly impact revenue.
Commodity Price Volatility & Weather: Fluctuations in agricultural commodity prices affect farmer profitability and their ability to purchase agrochemicals. Adverse weather patterns can also impact demand.
Currency Fluctuations: Operating in numerous countries exposes the company to currency exchange rate risks.
Intense Competition: The generic agrochemical market is highly competitive, leading to pricing pressures.
Supply Chain Disruptions: Reliance on third-party manufacturers and global logistics means potential vulnerability to disruptions.
Dependence on Key Active Ingredients: Over-reliance on a few blockbuster molecules could pose a risk if those face regulatory challenges.
Management & Ownership
Sharda Cropchem is primarily a promoter-led company, with Mr. R.S. Bubna being the Chairman and Managing Director. The Bubna family holds a significant stake in the company, ensuring aligned long-term interests. The management team is generally viewed as experienced in the agrochemical sector, having successfully scaled the company's global operations and registration capabilities over the years. The promoter group maintains a substantial ownership stake, alongside holdings by institutional investors and the public.
Outlook
Sharda Cropchem operates in an essential industry with consistent underlying demand for crop protection. Its asset-light, registration-focused model has proven effective for global market penetration in the generic agrochemical space. The continuous addition of new product registrations and geographical expansion provide a clear pathway for future growth. However, the company faces inherent risks associated with regulatory changes, intense competition, and agricultural sector cyclicality. While its robust registration portfolio provides a defensive moat, the ability to navigate evolving global regulations and maintain competitive pricing will be crucial for sustained performance. The non-agrochemicals segment offers diversification, but agrochemicals will likely remain the primary revenue driver, tying its fortune closely to global agricultural trends and regulatory environments.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 1312 | 785 | 777 | 929 | 1829 | 985 | 929 | 1289 | 2065 | 1074 |
| Other Income | -2 | 19 | 34 | 1 | 36 | 32 | 29 | 21 | 22 | 35 |
| Total Income | 1310 | 804 | 811 | 930 | 1864 | 1017 | 958 | 1310 | 2087 | 1108 |
| Total Expenditure | 1057 | 708 | 696 | 815 | 1536 | 770 | 796 | 1048 | 1578 | 888 |
| Operating Profit | 253 | 96 | 115 | 115 | 328 | 248 | 162 | 262 | 510 | 221 |
| Interest | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 |
| Depreciation | 54 | 65 | 69 | 69 | 72 | 78 | 76 | 83 | 87 | 100 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 198 | 31 | 46 | 46 | 256 | 169 | 86 | 179 | 422 | 118 |
| Provision for Tax | 55 | 4 | 3 | 15 | 53 | 26 | 11 | 33 | 103 | 30 |
| Profit After Tax | 143 | 27 | 42 | 31 | 204 | 143 | 74 | 145 | 319 | 88 |
| Adjustments | -0 | 0 | -0 | 0 | -0 | -0 | -0 | 0 | -0 | 0 |
| Profit After Adjustments | 143 | 27 | 42 | 31 | 204 | 143 | 74 | 145 | 319 | 88 |
| Adjusted Earnings Per Share | 15.9 | 3 | 4.7 | 3.5 | 22.6 | 15.8 | 8.2 | 16.1 | 35.3 | 9.8 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 1222 | 1399 | 1707 | 1998 | 2003 | 2396 | 3580 | 4045 | 3163 | 4320 | 5268 | 5357 |
| Other Income | 25 | 16 | 17 | 21 | 43 | 66 | 29 | 40 | 60 | 60 | 142 | 107 |
| Total Income | 1248 | 1415 | 1723 | 2018 | 2046 | 2461 | 3609 | 4085 | 3223 | 4379 | 5410 | 5463 |
| Total Expenditure | 943 | 1078 | 1351 | 1664 | 1708 | 1965 | 2884 | 3386 | 2860 | 3705 | 4209 | 4310 |
| Operating Profit | 305 | 337 | 372 | 355 | 338 | 496 | 725 | 699 | 363 | 674 | 1201 | 1155 |
| Interest | 8 | 9 | 15 | 20 | 16 | 16 | 15 | 20 | 24 | 21 | 21 | 2 |
| Depreciation | 35 | 56 | 70 | 99 | 137 | 170 | 245 | 248 | 267 | 275 | 325 | 346 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 261 | 272 | 287 | 235 | 185 | 309 | 464 | 431 | 72 | 378 | 856 | 805 |
| Provision for Tax | 86 | 81 | 96 | 59 | 20 | 80 | 115 | 89 | 40 | 74 | 175 | 177 |
| Profit After Tax | 175 | 190 | 191 | 176 | 165 | 229 | 349 | 342 | 32 | 304 | 681 | 626 |
| Adjustments | -0 | 0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | 0 |
| Profit After Adjustments | 175 | 190 | 191 | 176 | 165 | 229 | 349 | 342 | 32 | 304 | 681 | 626 |
| Adjusted Earnings Per Share | 19.4 | 21.1 | 21.1 | 19.5 | 18.3 | 25.4 | 38.7 | 37.9 | 3.5 | 33.7 | 75.5 | 69.4 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 22% | 9% | 17% | 16% |
| Operating Profit CAGR | 78% | 20% | 19% | 15% |
| PAT CAGR | 124% | 26% | 24% | 15% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -13% | 19% | 17% | 6% |
| ROE Average | 24% | 13% | 15% | 16% |
| ROCE Average | 31% | 17% | 20% | 23% |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 805 | 960 | 1135 | 1284 | 1403 | 1614 | 1912 | 2232 | 2237 | 2501 | 3136 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 181 | 256 | 317 | 404 | 435 | 507 | 610 | 617 | 672 | 482 | 236 |
| Total Current Liabilities | 542 | 663 | 1078 | 822 | 856 | 1140 | 1693 | 2026 | 1581 | 1986 | 2518 |
| Total Liabilities | 1529 | 1879 | 2530 | 2510 | 2695 | 3261 | 4216 | 4876 | 4490 | 4969 | 5890 |
| Fixed Assets | 130 | 210 | 226 | 372 | 416 | 544 | 592 | 668 | 708 | 750 | 989 |
| Other Non-Current Assets | 383 | 460 | 665 | 590 | 597 | 617 | 771 | 894 | 844 | 632 | 332 |
| Total Current Assets | 1015 | 1209 | 1639 | 1548 | 1681 | 2100 | 2853 | 3314 | 2938 | 3586 | 4570 |
| Total Assets | 1529 | 1879 | 2530 | 2510 | 2695 | 3261 | 4216 | 4876 | 4490 | 4969 | 5890 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 38 | 32 | 72 | 61 | 51 | 78 | 86 | 57 | 176 | 87 | 127 |
| Cash Flow from Operating Activities | 197 | 181 | 17 | 556 | 146 | 246 | 267 | 328 | 341 | 604 | 656 |
| Cash Flow from Investing Activities | -120 | -104 | -163 | -360 | -68 | -282 | -208 | -145 | -393 | -510 | -513 |
| Cash Flow from Financing Activities | -89 | -38 | 132 | -215 | -60 | 43 | -91 | -97 | -37 | -68 | -118 |
| Net Cash Inflow / Outflow | -12 | 40 | -14 | -19 | 19 | 8 | -32 | 86 | -89 | 26 | 24 |
| Closing Cash & Cash Equivalent | 32 | 72 | 61 | 51 | 78 | 86 | 57 | 176 | 87 | 127 | 220 |
| # | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 19.41 | 21.11 | 21.14 | 19.55 | 18.25 | 25.4 | 38.71 | 37.9 | 3.53 | 33.74 | 75.47 |
| CEPS(Rs) | 23.3 | 27.34 | 28.9 | 30.56 | 33.45 | 44.3 | 65.91 | 65.41 | 33.15 | 64.19 | 111.45 |
| DPS(Rs) | 3 | 4 | 4 | 4 | 4 | 5 | 6 | 6 | 3 | 9 | 15 |
| Book NAV/Share(Rs) | 89.28 | 106.39 | 125.78 | 142.31 | 155.49 | 178.93 | 211.98 | 247.4 | 247.96 | 277.16 | 347.65 |
| Core EBITDA Margin(%) | 22.85 | 22.99 | 20.85 | 16.72 | 14.72 | 17.96 | 19.43 | 16.29 | 8.67 | 13.53 | 18.99 |
| EBIT Margin(%) | 22.06 | 20.09 | 17.72 | 12.78 | 10.03 | 13.59 | 13.39 | 11.15 | 2.75 | 8.8 | 15.72 |
| Pre Tax Margin(%) | 21.38 | 19.42 | 16.83 | 11.77 | 9.23 | 12.92 | 12.97 | 10.65 | 2.05 | 8.32 | 15.34 |
| PAT Margin (%) | 14.34 | 13.6 | 11.18 | 8.83 | 8.22 | 9.57 | 9.76 | 8.45 | 0.91 | 6.7 | 12.21 |
| Cash Profit Margin (%) | 17.2 | 17.63 | 15.28 | 13.8 | 15.07 | 16.68 | 16.61 | 14.59 | 8.55 | 12.74 | 18.03 |
| ROA(%) | 12.97 | 11.17 | 8.65 | 7 | 6.33 | 7.7 | 9.34 | 7.52 | 0.68 | 6.44 | 12.54 |
| ROE(%) | 24 | 21.57 | 18.22 | 14.58 | 12.26 | 15.19 | 19.81 | 16.5 | 1.43 | 12.85 | 24.16 |
| ROCE(%) | 35.95 | 31.81 | 26.71 | 19.72 | 14.95 | 21.11 | 26.39 | 21.55 | 4.29 | 16.87 | 31.1 |
| Receivable days | 160.44 | 168.58 | 167.3 | 155.62 | 164.03 | 163.9 | 137.78 | 152.19 | 173.75 | 138.64 | 142.2 |
| Inventory Days | 44.71 | 58.38 | 87.49 | 81.8 | 68.08 | 69.16 | 72.31 | 91.45 | 110.89 | 78.83 | 68.45 |
| Payable days | 142.38 | 171.07 | 174.12 | 167.07 | 173.85 | 166.59 | 144.87 | 163 | 179.1 | 134.48 | 151.79 |
| PER(x) | 12.02 | 23.07 | 18.12 | 19.05 | 5.89 | 11.31 | 15.89 | 12.9 | 90.82 | 16.92 | 11.52 |
| Price/Book(x) | 2.61 | 4.58 | 3.05 | 2.62 | 0.69 | 1.61 | 2.9 | 1.98 | 1.29 | 2.06 | 2.5 |
| Dividend Yield(%) | 1.29 | 0.82 | 1.04 | 1.07 | 3.72 | 1.74 | 0.98 | 1.23 | 0.93 | 1.58 | 1.72 |
| EV/Net Sales(x) | 1.67 | 3.06 | 2.07 | 1.62 | 0.41 | 1 | 1.51 | 1.05 | 0.89 | 1.14 | 1.45 |
| EV/Core EBITDA(x) | 6.71 | 12.7 | 9.47 | 9.12 | 2.42 | 4.83 | 7.48 | 6.06 | 7.74 | 7.31 | 6.35 |
| Net Sales Growth(%) | 15.18 | 14.49 | 21.97 | 17.05 | 0.27 | 19.6 | 49.43 | 13 | -21.81 | 36.57 | 21.94 |
| EBIT Growth(%) | 45.97 | 4.25 | 7.6 | -15.61 | -21.3 | 62.13 | 47.15 | -5.91 | -78.7 | 316.21 | 119.26 |
| PAT Growth(%) | 42.47 | 8.66 | 0.21 | -7.56 | -6.61 | 39.18 | 52.38 | -2.09 | -90.67 | 854.1 | 123.7 |
| EPS Growth(%) | 42.41 | 8.74 | 0.17 | -7.56 | -6.62 | 39.18 | 52.4 | -2.09 | -90.68 | 854.67 | 123.69 |
| Debt/Equity(x) | 0 | 0 | 0.15 | 0 | 0 | 0.04 | 0.02 | 0 | 0 | 0 | 0 |
| Current Ratio(x) | 1.87 | 1.82 | 1.52 | 1.88 | 1.96 | 1.84 | 1.69 | 1.64 | 1.86 | 1.81 | 1.82 |
| Quick Ratio(x) | 1.58 | 1.39 | 1.03 | 1.45 | 1.52 | 1.38 | 1.16 | 1.08 | 1.23 | 1.32 | 1.37 |
| Interest Cover(x) | 32.37 | 30.12 | 19.82 | 12.62 | 12.55 | 20.07 | 31.94 | 22.35 | 3.97 | 18.6 | 41.43 |
| Total Debt/Mcap(x) | 0 | 0 | 0.05 | 0 | 0 | 0.03 | 0.01 | 0 | 0 | 0 | 0 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 74.82 | 74.82 | 74.82 | 74.82 | 74.82 | 74.82 | 74.82 | 74.82 | 74.82 | 74.82 |
| FII | 2.14 | 2.02 | 2.52 | 3.77 | 4.69 | 5.48 | 5.26 | 4.2 | 4.6 | 3.11 |
| DII | 12.41 | 12.87 | 12.76 | 10.07 | 10.27 | 9.38 | 9.26 | 9.95 | 9.69 | 9.18 |
| Public | 10.63 | 10.28 | 9.9 | 11.34 | 10.21 | 10.32 | 10.65 | 11.02 | 10.88 | 12.88 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 6.75 | 6.75 | 6.75 | 6.75 | 6.75 | 6.75 | 6.75 | 6.75 | 6.75 | 6.75 |
| FII | 0.19 | 0.18 | 0.23 | 0.34 | 0.42 | 0.49 | 0.47 | 0.38 | 0.42 | 0.28 |
| DII | 1.12 | 1.16 | 1.15 | 0.91 | 0.93 | 0.85 | 0.84 | 0.9 | 0.87 | 0.83 |
| Public | 0.96 | 0.93 | 0.89 | 1.02 | 0.92 | 0.93 | 0.96 | 0.99 | 0.98 | 1.16 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9.02 | 9.02 | 9.02 | 9.02 | 9.02 | 9.02 | 9.02 | 9.02 | 9.02 | 9.02 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +22% | +9% | +17% | +16% |
| Operating Profit CAGR | +78% | +20% | +19% | +15% |
| PAT CAGR | +124% | +26% | +24% | +15% |
| Share Price CAGR | -13% | +19% | +17% | +6% |
| ROE Average | +24% | +13% | +15% | +16% |
| ROCE Average | +31% | +17% | +20% | +23% |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 74.82 | 74.82 | 74.82 | 74.82 | 74.82 | 74.82 | 74.82 | 74.82 | 74.82 | 74.82 |
| FII | 2.14 | 2.02 | 2.52 | 3.77 | 4.69 | 5.48 | 5.26 | 4.2 | 4.6 | 3.11 |
| DII | 12.41 | 12.87 | 12.76 | 10.07 | 10.27 | 9.38 | 9.26 | 9.95 | 9.69 | 9.18 |
| Public | 10.63 | 10.28 | 9.9 | 11.34 | 10.21 | 10.32 | 10.65 | 11.02 | 10.88 | 12.88 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 6.75 | 6.75 | 6.75 | 6.75 | 6.75 | 6.75 | 6.75 | 6.75 | 6.75 | 6.75 |
| FII | 0.19 | 0.18 | 0.23 | 0.34 | 0.42 | 0.49 | 0.47 | 0.38 | 0.42 | 0.28 |
| DII | 1.12 | 1.16 | 1.15 | 0.91 | 0.93 | 0.85 | 0.84 | 0.9 | 0.87 | 0.83 |
| Public | 0.96 | 0.93 | 0.89 | 1.02 | 0.92 | 0.93 | 0.96 | 0.99 | 0.98 | 1.16 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9.02 | 9.02 | 9.02 | 9.02 | 9.02 | 9.02 | 9.02 | 9.02 | 9.02 | 9.02 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.